Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(2.77)
# 1,758
Out of 5,127 analysts
54
Total ratings
39.13%
Success rate
10.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Overweight | n/a | $16.99 | - | 1 | Dec 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Upgrades: Overweight | n/a | $488.26 | - | 5 | Nov 5, 2025 | |
| ATYR aTyr Pharma | Downgrades: Neutral | n/a | $0.90 | - | 2 | Sep 15, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Overweight | n/a | $14.01 | - | 1 | Aug 15, 2025 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $78.93 | -17.65% | 13 | Jun 23, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $10.71 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $30.07 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $3.69 | - | 1 | Mar 18, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $17.53 | - | 3 | Jan 21, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Overweight | $10 | $4.50 | +122.22% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.75 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $57.77 | - | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $29.58 | -18.86% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.69 | +16,628.62% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $12.27 | +22.25% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $1.51 | +827.15% | 1 | Mar 3, 2021 |
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: n/a
Current: $16.99
Upside: -
Madrigal Pharmaceuticals
Nov 5, 2025
Upgrades: Overweight
Price Target: n/a
Current: $488.26
Upside: -
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.90
Upside: -
Avalo Therapeutics
Aug 15, 2025
Initiates: Overweight
Price Target: n/a
Current: $14.01
Upside: -
Structure Therapeutics
Jun 23, 2025
Reiterates: Overweight
Price Target: $65
Current: $78.93
Upside: -17.65%
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.71
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $30.07
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.69
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $17.53
Upside: -
TriSalus Life Sciences
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $4.50
Upside: +122.22%
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.75
Upside: -
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $57.77
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $29.58
Upside: -18.86%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $2.69
Upside: +16,628.62%
May 18, 2021
Initiates: Buy
Price Target: $15
Current: $12.27
Upside: +22.25%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $1.51
Upside: +827.15%